{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:02Z","timestamp":1791908162916,"version":"4.3.4"},"reference-count":23,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors\u2014alone or in combination with cytotoxic T-lymphocyte\u2013associated protein 4 or lymphocyte-activation gene 3 inhibitors\u2014demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela\/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela\/nivo followed by ipilimumab+nivolumab (ipi\/nivo) (arm A, N=40), ipi\/nivo followed by rela\/nivo (arm B, N=71), and anti-PD-1 followed by rela\/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicate that rela\/nivo may remain active following anti-PD-1 or ipi\/nivo therapy. Additionally, our results suggest that sequencing ipi\/nivo before rela\/nivo may yield better outcomes than starting with rela\/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012225","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T20:35:14Z","timestamp":1764362114000},"page":"e012225","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["International real-world study of combination immunotherapy sequences in metastatic melanoma"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-2670","authenticated-orcid":false,"given":"Mora","family":"Guardamagna","sequence":"first","affiliation":[{"name":"D\u00e9partement de m\u00e9decine oncologique, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E","family":"Lochrin","sequence":"additional","affiliation":[{"name":"Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3126-1193","authenticated-orcid":false,"given":"James William","family":"Smithy","sequence":"additional","affiliation":[{"name":"Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-7961","authenticated-orcid":false,"given":"Michael","family":"Postow","sequence":"additional","affiliation":[{"name":"Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gaudy-Marqueste","sequence":"additional","affiliation":[{"name":"Dermatology and Skin Cancer, Aix-Marseille University, Marseille, France"},{"name":"INSERM U1068, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausicaa","family":"Malissen","sequence":"additional","affiliation":[{"name":"Dermatology and Skin Cancer, Aix-Marseille University, Marseille, France"},{"name":"INSERM U1068, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Monestier","sequence":"additional","affiliation":[{"name":"Dermatology and Skin Cancer, Aix-Marseille University, Marseille, France"},{"name":"INSERM U1068, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane A","family":"Czapla","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleigha R","family":"Lawless","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-8906","authenticated-orcid":false,"given":"Ines","family":"Pires da Silva","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"},{"name":"The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"},{"name":"The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-7562","authenticated-orcid":false,"given":"Alexander Maxwell","family":"Menzies","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, North Sydney, New South Wales, Australia"},{"name":"The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-3372","authenticated-orcid":false,"given":"Florentia","family":"Dimitriou","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Zurich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Dermatology, University Hospital Zurich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Marchi","sequence":"additional","affiliation":[{"name":"Dermatology, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Chaurand","sequence":"additional","affiliation":[{"name":"Dermatology, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[{"name":"Dermatology, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Paone","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Arianna","family":"Facchini","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6625-448X","authenticated-orcid":false,"given":"Govind","family":"Warrier","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"},{"name":"Johns Hopkins University The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2976-0911","authenticated-orcid":false,"given":"Evan J","family":"Lipson","sequence":"additional","affiliation":[{"name":"Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"},{"name":"Johns Hopkins University The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Erdmann","sequence":"additional","affiliation":[{"name":"Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Comprehensive Cancer Center Erlangen, Erlangen, Germany"},{"name":"Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[{"name":"Dermatology, Uniklinikum Erlangen, Deutsches Zentrum Immuntherapie (DZI), Comprehensive Cancer Center Erlangen, Erlangen, Germany"},{"name":"Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Archambaud","sequence":"additional","affiliation":[{"name":"D\u00e9partement de biostatistiques et d'\u00e9pid\u00e9miologie, Gustave Roussy, Villejuif, France"},{"name":"Oncostat, INSERM U1018, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Roy","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine oncologique, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Routier","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine oncologique, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5659-8791","authenticated-orcid":false,"given":"Celine","family":"Boutros","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine oncologique, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Jamme","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine oncologique, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djaouida","family":"Belkadi-Sadou","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine oncologique, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemie","family":"Simon-Tillaux","sequence":"additional","affiliation":[{"name":"D\u00e9partement de biostatistiques et d'\u00e9pid\u00e9miologie, Gustave Roussy, Villejuif, France"},{"name":"Oncostat, INSERM U1018, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0238","authenticated-orcid":false,"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine oncologique, Gustave Roussy, Villejuif, France"},{"name":"Universit\u00e9 Paris-Saclay, Gustave Roussy, Inserm Pr\u00e9dicteurs mol\u00e9culaires et nouvelles cibles en oncologie, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2026091123004194000_13.11.e012225.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2026091123004194000_13.11.e012225.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059"},{"key":"2026091123004194000_13.11.e012225.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2026091123004194000_13.11.e012225.4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evid"},{"key":"2026091123004194000_13.11.e012225.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2026091123004194000_13.11.e012225.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.009"},{"key":"2026091123004194000_13.11.e012225.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00079"},{"key":"2026091123004194000_13.11.e012225.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00097-8"},{"key":"2026091123004194000_13.11.e012225.9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026091123004194000_13.11.e012225.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002092","article-title":"Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort","volume":"9","author":"Bai","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026091123004194000_13.11.e012225.11","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw323"},{"key":"2026091123004194000_13.11.e012225.12","doi-asserted-by":"crossref","first-page":"S1290","DOI":"10.1016\/j.annonc.2023.10.045","article-title":"LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047","volume":"34","author":"Lipson","year":"2023","journal-title":"Ann Oncol"},{"key":"2026091123004194000_13.11.e012225.13","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2019.01.003"},{"key":"2026091123004194000_13.11.e012225.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01136"},{"key":"2026091123004194000_13.11.e012225.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02498-y"},{"key":"2026091123004194000_13.11.e012225.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003853","article-title":"Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses","volume":"10","author":"Friedman","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026091123004194000_13.11.e012225.17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/CMR.0000000000000760","article-title":"Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure","volume":"31","author":"Klee","year":"2021","journal-title":"Melanoma Res"},{"key":"2026091123004194000_13.11.e012225.18","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1200\/JCO.2019.37.15_suppl.9505","article-title":"Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry","volume":"37","author":"Weichenthal","year":"2019","journal-title":"JCO"},{"key":"2026091123004194000_13.11.e012225.19","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1056\/NEJMc2119768","article-title":"CTLA-4 Blockade Resistance after Relatlimab and Nivolumab","volume":"386","author":"Menzies","year":"2022","journal-title":"N Engl J Med"},{"key":"2026091123004194000_13.11.e012225.20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02072"},{"key":"2026091123004194000_13.11.e012225.21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e21533","article-title":"Efficacy of nivolumab and relatlimab-rmbw in patients with advanced melanoma who were previously treated with PD-1 inhibitor: Real world experience","volume":"41","author":"Jang","year":"2023","journal-title":"JCO"},{"key":"2026091123004194000_13.11.e012225.22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccell.2022.06.005","article-title":"Sex and cancer immunotherapy: Current understanding and challenges","volume":"40","author":"Pala","year":"2022","journal-title":"Cancer Cell"},{"key":"2026091123004194000_13.11.e012225.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30261-4"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:01:07Z","timestamp":1789192867000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,28]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jitc-2025-012225"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012225","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}